These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg; 1981 Nov; 82(5):649-57. PubMed ID: 7029149 [TBL] [Abstract][Full Text] [Related]
4. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Yasumoto K; Manabe H; Yanagawa E; Nagano N; Ueda H; Hirota N; Ohta M; Nomoto K; Azuma I; Yamamura Y Cancer Res; 1979 Aug; 39(8):3262-7. PubMed ID: 222448 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Järvinen R; Kaasinen E; Sankila A; Rintala E; Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154 [TBL] [Abstract][Full Text] [Related]
7. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer. Wright PW; Hill LD; Peterson AV; Pinkham R; Johnson L; Ivey T; Bernstein I; Bagley C; Anderson R Cancer Treat Rep; 1978 Nov; 62(11):1671-5. PubMed ID: 215304 [TBL] [Abstract][Full Text] [Related]
8. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
9. BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Hadźiev S; Mandulova P; Kavaklieva-Dimitrova J; Penev K; Spassova M; Madźarova S Neoplasma; 1982; 29(1):93-110. PubMed ID: 6280082 [TBL] [Abstract][Full Text] [Related]
10. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Matthay RA; Mahler DA; Beck GJ; Loke J; Baue AE; Carter DC; Mitchell MS Cancer Res; 1986 Nov; 46(11):5963-8. PubMed ID: 3530442 [TBL] [Abstract][Full Text] [Related]
11. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Winters WD; Lamm DL Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoimmunotherapy for gastric carcinoma. Makowka L; Falk RE; Ambus U; Bugala R; Landi S Can J Surg; 1980 Sep; 23(5):429-31. PubMed ID: 6159957 [TBL] [Abstract][Full Text] [Related]
14. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of intraoperative pleural lavage cytology for lung cancer without carcinomatous pleuritis: importance in patients with early stage disease during long-term follow-up. Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Takenaka A; Nakayama T; Yoneda G Eur J Cardiothorac Surg; 2009 Feb; 35(2):337-42. PubMed ID: 19041255 [TBL] [Abstract][Full Text] [Related]
16. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma. Leblanc B; Duclos AJ; Bénard F; Valiquette L; Paquin JM; Lapointe S; Mauffette F; Pharand D; Faucher R; Drouin G; Perreault JP Can J Urol; 2000 Feb; 7(1):944-8. PubMed ID: 11121250 [TBL] [Abstract][Full Text] [Related]
17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
18. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396 [TBL] [Abstract][Full Text] [Related]
19. Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy. Hadźiev S; Kavaklieva-Dimitrova J; Mandulova P; Madźarova S; Spassova M Neoplasma; 1980; 27(1):83-94. PubMed ID: 7374861 [TBL] [Abstract][Full Text] [Related]
20. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]